Last reviewed · How we verify
Trivalent split Inf
Trivalent split influenza vaccine stimulates the immune system to produce antibodies against three strains of influenza virus.
Trivalent split influenza vaccine stimulates the immune system to produce antibodies against three strains of influenza virus. Used for Seasonal influenza prevention in adults and children.
At a glance
| Generic name | Trivalent split Inf |
|---|---|
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated (split) viral antigens from three influenza strains (typically two A subtypes and one B type). When administered, these antigens trigger both humoral and cellular immune responses, leading to the production of strain-specific antibodies and memory B cells that provide protection against infection with matching circulating influenza viruses.
Approved indications
- Seasonal influenza prevention in adults and children
Common side effects
- Injection site soreness or erythema
- Myalgia
- Headache
- Low-grade fever
Key clinical trials
- Proteomic Profiling for Influenza (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: